Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 0 ( Mark One ) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from FORM 10 - K British Columbia ( State or other jurisdiction of incorporation or organization ) Two Carlson Parkway , Suite 260 Minneapolis , Minnesota ( Address of principal executive offices ) Title of each class Voting Common Shares , no par value per share or Commission file number : 001-36291 DIAMEDICA THERAPEUTICS INC . ( Exact name of registrant as specified in its charter ) to Registrant's telephone number , including area code : ( 763 ) 612-6755 Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) DMAC Not Applicable ( I.R.S. Employer Identification No. ) Accelerated filer Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . YES NO Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . YES NO Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . YES NO > 55447 ( Zip Code ) Name of each exchange on which registered The Nasdaq Capital Market Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( § 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . YES | NO Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company or an emerging growth company . See the definitions of “ large accelerated filer , ” “ accelerated filer , ” “ smaller reporting company ” and “ emerging growth company ” in Rule 12b - 2 of the Exchange Act . Smaller reporting company Large accelerated filer Emerging growth company Non - accelerated filer > If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . > Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . DOCUMENTS INCORPORATED BY REFERENCE Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Act ) . YES NO The aggregate market value of the registrant's voting common shares held by non - affiliates , computed by reference to the closing sales price at which the voting common shares were last sold as of June 30 , 2020 ( the last business day of the registrant's most recently completed second fiscal quarter ) , as reported by The Nasdaq Capital Market on that date , was $ 78.5 million . As of March 8 , 2021 , there were 18,776,157 voting common shares outstanding . Part III of this Annual Report on Form 10 - K incorporates by reference information ( to the extent specific sections are referred to herein ) from the registrant's Proxy Statement for its 2021 Annual General Meeting of Shareholders to be held May 25 , 2021 .